Does Pseudomyxoma Peritonei have a cure?

Currently, there is no single "cure" for Pseudomyxoma Peritonei (PMP), but it is often managed as a chronic condition with high rates of long-term survival. Through specialized surgical interventions and targeted therapies, many patients achieve multi-year remission, effectively turning Pseudomyxoma Peritonei into a manageable disease rather than a terminal diagnosis.

Is there a definitive cure for Pseudomyxoma Peritonei?

While no universal cure exists, the standard of care for Pseudomyxoma Peritonei—often involving Cytoreductive Surgery (CRS) combined with Hyperthermic Intraperitoneal Chemotherapy (HIPEC)—can be curative for many patients, particularly those with low-grade disease. For those with more aggressive forms of Pseudomyxoma Peritonei, treatment focuses on disease modification and symptom control, aiming to remove bulk tumor tissue and prolong life significantly.

What are the current treatment strategies?

Management of Pseudomyxoma Peritonei is highly specialized and typically requires high-volume centers. Current approaches include:

• Cytoreductive Surgery (CRS): The surgical removal of all visible tumor deposits within the abdominal cavity.


• HIPEC: Heated chemotherapy delivered directly into the abdomen during surgery to kill microscopic cancer cells.


• Systemic Chemotherapy: Used in cases where Pseudomyxoma Peritonei is unresectable or has recurred, to slow tumor progression.


• Palliative Care: Specialized support to manage symptoms like bowel obstruction or pain, ensuring the best possible quality of life.

What does the future of research look like?

Research into Pseudomyxoma Peritonei is shifting toward precision medicine. Scientists are currently investigating the molecular profile of these tumors to identify specific mutations that might respond to targeted therapies. While gene therapy is not yet a standard treatment, clinical trials are exploring novel biological agents and immunotherapy combinations. The 110 members of the DiseaseMaps community currently navigating Pseudomyxoma Peritonei highlight the importance of staying connected to evolving clinical data and trial opportunities.

Next steps

• Seek a consultation at a specialized center with high-volume experience in CRS and HIPEC.


• Monitor ClinicalTrials.gov for active studies investigating new chemotherapy agents for peritoneal surface malignancies.


• Join the DiseaseMaps.org community to share experiences and stay updated on the latest peer-reviewed research.


• Maintain regular surveillance imaging as recommended by your surgical oncologist to detect recurrence early.

Medical disclaimer: This information is for educational purposes only and does not replace professional medical advice, diagnosis, or treatment.

References

• NIH Genetic and Rare Diseases Information Center (GARD)


• Orphanet: Portal for rare diseases and orphan drugs


• Pseudomyxoma Survivor (Patient Advocacy Organization)


• PubMed: Clinical studies on CRS and HIPEC outcomes